慢性乙型肝炎抗病毒治疗进展(5)
[19]Lok AS，Trinh H，Carosi G，et al.Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B[J].Gastroenterology，2012，143(3)：619-628.
[20]周一鳴，曹建彪，闻炜，等.乙型肝炎病毒变异后果及原因分析[J].胃肠病学和肝病学杂志，2011，20(11)：1035-1037.
[21]Liaw YF，Gane E，Leung N，et al.2-Year GLOBE trial results： telbivudine is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology，2009，136(2)：486-495.
, http://www.100md.com
[22]Lai CL，Gane E，Liaw YF，et al.Telbivudine versus lamivudine in patients with chronic hepatitis B[J].N Engl J Med，2007，357(25)：2576-2588.
[23]Han GR，Cao MK，Zhao W，et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J].J Hepatol，2011，55(6)：1215-1221.
[24]Gish RG，Clark MD，Kane SD，et al.Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B[J].Clin Gastroenterol Hepatol，2012，10(8)：941-946.
, 百拇医药
[25]Marcellin P，Heathcote EJ，Buti M，et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J].N Engl J Med，2008，359(23)：2442-2455.
[26]Heathcote EJ，Marcellin P，Buti M，et al.Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B[J].Gastroenterology，2011，140(1)：132-143.
[27]Brouwer WP，Xie Q，Sonneveld MJ，et al.Adding peginterferon to entecavir for HBeAg-positive chronic hepatitis B： A multicentre randomized trial (ARES study)[J].Hepatology，2015，61(5)：1512-1522.
, 百拇医药
[28]Kittner JM，Sprinzl MF，Grambihler A，et al.Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B[J].J Clin Virol，2012，54(1)：93-95.
[29]Ning Q，Han MF，Sun YT，et al.Switching from entecavir to Peg IFN alfa-2a in patients with HBeAg-positive chronic hepatitis B： A randomised open-label trial (OSST trial)[J].J Hepatol，2014，61(4)：777-784.
[30]Hu P，Jia S，Zhang WH，et al.A multi-center randomized study on the efficacy and safety of switching to peginterferonα-2a (40 KD)for 48 or 96 weeks in HBeAg positive CHB patients with a prior NUC history for 1 to 3 years： an interim analysis of NEW SWITCH study[J].Hepatology，2014，60(6)：1273A-1274A.
[31]Ouzan D，Pénaranda G，Joly H，et al.Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs[J].J Clin Virol，2013，58(4)：713-717., 百拇医药(汪晓凤 邵和军)
[20]周一鳴，曹建彪，闻炜，等.乙型肝炎病毒变异后果及原因分析[J].胃肠病学和肝病学杂志，2011，20(11)：1035-1037.
[21]Liaw YF，Gane E，Leung N，et al.2-Year GLOBE trial results： telbivudine is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology，2009，136(2)：486-495.
, http://www.100md.com
[22]Lai CL，Gane E，Liaw YF，et al.Telbivudine versus lamivudine in patients with chronic hepatitis B[J].N Engl J Med，2007，357(25)：2576-2588.
[23]Han GR，Cao MK，Zhao W，et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J].J Hepatol，2011，55(6)：1215-1221.
[24]Gish RG，Clark MD，Kane SD，et al.Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B[J].Clin Gastroenterol Hepatol，2012，10(8)：941-946.
, 百拇医药
[25]Marcellin P，Heathcote EJ，Buti M，et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J].N Engl J Med，2008，359(23)：2442-2455.
[26]Heathcote EJ，Marcellin P，Buti M，et al.Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B[J].Gastroenterology，2011，140(1)：132-143.
[27]Brouwer WP，Xie Q，Sonneveld MJ，et al.Adding peginterferon to entecavir for HBeAg-positive chronic hepatitis B： A multicentre randomized trial (ARES study)[J].Hepatology，2015，61(5)：1512-1522.
, 百拇医药
[28]Kittner JM，Sprinzl MF，Grambihler A，et al.Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B[J].J Clin Virol，2012，54(1)：93-95.
[29]Ning Q，Han MF，Sun YT，et al.Switching from entecavir to Peg IFN alfa-2a in patients with HBeAg-positive chronic hepatitis B： A randomised open-label trial (OSST trial)[J].J Hepatol，2014，61(4)：777-784.
[30]Hu P，Jia S，Zhang WH，et al.A multi-center randomized study on the efficacy and safety of switching to peginterferonα-2a (40 KD)for 48 or 96 weeks in HBeAg positive CHB patients with a prior NUC history for 1 to 3 years： an interim analysis of NEW SWITCH study[J].Hepatology，2014，60(6)：1273A-1274A.
[31]Ouzan D，Pénaranda G，Joly H，et al.Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs[J].J Clin Virol，2013，58(4)：713-717., 百拇医药(汪晓凤 邵和军)